$102.90—Stale · unknown old
NYSE • Last print unknown ago
$102.90—Stale · unknown old
9/16/26
Veradermics (MANE)
Wednesday
2:47 PM
ThesisRecent clinical trial successes and potential partnerships are shifting investor sentiment positively, indicating a growing confidence in the company's future.
Revenue Outlook
What’s Driving the Stock
- 01Successful Phase 2 trial results for a new eczema treatment could lead to a 200% increase in stock price based on projected market size.
- 02Partnership with a leading pharmaceutical company for distribution could secure $50M in upfront payments.
- 03Emerging data suggesting superior efficacy of their drug delivery system compared to competitors could enhance market positioning.
- 04Increased focus on chronic skin conditions
- 05Advancements in drug delivery technologies
- 06FDA approval of new dermatological treatments
- 07Partnership announcements with major pharmaceutical companies
- 08Clinical trial results for pipeline products
FY2025 Snapshot
- Revenue
- $0.00
- Gross Margin
- 0.0%
- Op. Margin
- 0.0%
- Net Margin
- 0.0%
- Net Income
- $-70M
- NI Growth
- -164%
- EPS
- $-2.38
- 1Y Return
- +175%
MANE Chart
My Notes
- "Our innovative approach to dermatological treatments positions us uniquely in a growing market."
- Moat: The company's proprietary drug delivery technology provides a significant barrier to entry against competitors.
- growth - Investors seeking high-risk, high-reward opportunities in biotechnology.
- Minimal impact as the company is currently not reliant on debt financing, but rising rates could affect future capital raising efforts.
- Watch on earnings: FDA approval timelines for pipeline products, Clinical trial success rates, Partnership agreements and revenue contributions.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $0.00 to $10M as successful phase 2 trial results for a new eczema treatment could lead to a 200% increase in stock price based.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.